Trial Profile
A Randomized Phase II Study of Oral Panobinostat (LBH589) With or Without Rituximab to Treat Relapsed or Refractory Diffuse Large B Cell Lymphoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2023
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 23 Mar 2023 Status changed from active, no longer recruiting to completed.
- 20 Sep 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016.
- 10 May 2016 Results analyzing response to panobinostat treatment in a subset of patients along with biomarker analysis published in the Blood.